Cure8 research brief
A formulation that targets and sustains budesonide release in the intestine could improve local anti-inflammatory effects and reduce systemic exposure compared with standard oral formulations. If translational studies confirm safety and benefit, it might lead to new oral treatments for ulcerative colitis.
Researchers in drug delivery and IBD therapeutics, clinical investigators designing translational studies, and clinicians interested in new localized steroid delivery approaches.
The researchers developed a cytosol-hydrogelled Chlorella pyrenoidosa carrier that traps budesonide under acidic (stomach) conditions and releases it in the intestine, without requiring traditional enteric coatings. Loading used two approved excipients (Labrasol and Soluplus) to form a thermosensitive in-situ gel.
In mice with DSS-induced colitis the formulation increased local drug retention and lowered TNF-α and IL-6 while improving colon length versus non-hydrogelled controls. This report is an abstract-summary of a preclinical (animal) study in an academic journal.
It describes formulation and efficacy in mice; it does not provide clinical trial data in humans or safety data for patients. More work is needed before this approach could be tested in people.
This is preclinical, based on a mouse DSS-colitis model and formulation experiments described in the article abstract. It does not report human safety or efficacy. The paper focuses on a formulation strategy using microalgae components and approved excipients rather than clinical guidance.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Xiangrui Liu has patent #ZL202511505474.6 licensed to Innovation Center of Yangtze River Delta, Zhejiang University. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A pediatric trial of budesonide rectal foam could provide evidence about a locally acting steroid option for children with distal ulcerative colitis. Trial results may affect treatment choices for pediatric distal...
This trial investigates a new oral medication (PALI-2108) for moderate-to-severe ulcerative colitis and could expand treatment options if later trials show benefit and safety. The study focuses on clinical remission at...
The paper identifies subtype-specific changes in enteric glial cells and mast cell activity in microscopic colitis and shows some treatment-associated reductions after budesonide; that helps explain disease biology and...
